Corcept Therapeutics Incorporated CORT
116.10
(2.41)
(2.03%)
as of 25 Sep
- Market cap
- $12.9B
- P/E
- 223×
Follow CORT
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
16.47% | 14.79% | 7.07% | 8.08% | |
| 13.02% | 11.71% | 5.62% | 6.41% | ||
ROIC |
19.01% | 9.98% | (1.71%) | 1.01% | |
Return on Tangible Assets |
28.22% | 30.56% | 16.67% | 18.63% | |
Average Days of Receivables |
34.29 | 28.66 | 18.54 | 33.79 | |
Free Cash Flow per Share |
1.58 | 1.37 | 1.15 | 1.01 | |
Free Cash Flow |
163.32 | 141.79 | 120.15 | 106.92 | |
Capital Expenditures |
(0.28) | (0.21) | (0.31) | (2.78) | |
Piotroski F-Score |
5.00 | 4.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
15.45% | 13.85% | 12.34% | 10.82% | |
Accounts Receivable Turnover |
11.46 | 13.39 | 15.25 | 11.74 | |
Accounts Payable Turnover |
0.50 | 0.47 | 0.44 | 0.73 | |
Inventory Turnover |
1.31 | 1.03 | 0.99 | 1.11 | |
Average Days of Payables |
939.11 | 1,137.56 | 903.37 | 386.38 | |
Days of Inventory on Hand |
336.67 | 361.93 | 349.62 | 341.68 | |
Tax Rate |
0.20 | 0.50 | 2.90 | 1.09 | |
Research and Development Expense of Revenue |
35.13% | 33.48% | 33.86% | 30.56% | |
Selling, General and Administrative Expense of Revenue |
54.22% | 58.93% | 65.46% | 66.98% | |
Share Based Compensation of Revenue |
10.86% | 11.10% | 11.14% | 11.57% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.56 | 1.45 | 2.58 | 2.02 | |
Depreciation/Fixed assets |
(4.33) | (1.70) | (0.97) | (0.52) | |
Capex/Depreciation |
0.03 | 0.07 | 0.10 | 1.04 | |
Revenue per Share |
7.16 | 7.33 | 7.36 | 7.88 | |
Operating CF per Share |
1.58 | 1.37 | 1.15 | 1.04 | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
14.12% | 12.89% | 6.07% | 6.53% |
Columns are period end dates